Movement Alert｜Insilico Medicine Rises 5.92% in Regular Trading, Positive Profit Warning Signals First-Half Turnaround to Profitability

Market Focus

Jul 10

On July 10, Insilico Medicine rose 5.92% in regular trading, trading at 42.4 HKD/share with turnover of HKD 282 million, extending strong momentum following its positive profit warning issued the previous day.

On July 9, the company announced it expects first-half revenue of approximately USD 103 million to USD 107 million, representing growth of approximately 272.7% to 287.3% compared to USD 27.5 million in the same period last year. Net profit is expected at USD 33.5 million to USD 39.5 million, a significant turnaround from the net loss of USD 19.2 million recorded in the prior-year period. Adjusted non-IFRS net profit is projected at USD 45.5 million to USD 51.5 million versus an adjusted net loss of USD 15.4 million previously.

The earnings inflection reflects the company's multi-pronged commercial model combining pipeline out-licensing, co-development partnerships, and AI platform services. Recent catalysts include a USD 600 million strategic collaboration with Takeda Pharmaceutical announced on July 2, and the initiation of a Phase 3 clinical trial for its lead AI-discovered drug Rentosertib on July 8.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1141701482"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141701482\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141701482?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 10:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141701482","market":"us","top_or_hot":-1,"title":"Movement Alert｜Insilico Medicine Rises 5.92% in Regular Trading, Positive Profit Warning Signals First-Half Turnaround to Profitability","media":"Market Focus","content":"<p><p>On July 10, Insilico Medicine rose 5.92% in regular trading, trading at 42.4 HKD/share with turnover of HKD 282 million, extending strong momentum following its positive profit warning issued the previous day.</p><p>On July 9, the company announced it expects first-half revenue of approximately USD 103 million to USD 107 million, representing growth of approximately 272.7% to 287.3% compared to USD 27.5 million in the same period last year. Net profit is expected at USD 33.5 million to USD 39.5 million, a significant turnaround from the net loss of USD 19.2 million recorded in the prior-year period. Adjusted non-IFRS net profit is projected at USD 45.5 million to USD 51.5 million versus an adjusted net loss of USD 15.4 million previously.</p><p>The earnings inflection reflects the company's multi-pronged commercial model combining pipeline out-licensing, co-development partnerships, and AI platform services. Recent catalysts include a USD 600 million strategic collaboration with Takeda Pharmaceutical announced on July 2, and the initiation of a Phase 3 clinical trial for its lead AI-discovered drug Rentosertib on July 8.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Insilico Medicine Rises 5.92% in Regular Trading, Positive Profit Warning Signals First-Half Turnaround to Profitability</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Insilico Medicine Rises 5.92% in Regular Trading, Positive Profit Warning Signals First-Half Turnaround to Profitability\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-10 10:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 10, Insilico Medicine rose 5.92% in regular trading, trading at 42.4 HKD/share with turnover of HKD 282 million, extending strong momentum following its positive profit warning issued the previous day.</p><p>On July 9, the company announced it expects first-half revenue of approximately USD 103 million to USD 107 million, representing growth of approximately 272.7% to 287.3% compared to USD 27.5 million in the same period last year. Net profit is expected at USD 33.5 million to USD 39.5 million, a significant turnaround from the net loss of USD 19.2 million recorded in the prior-year period. Adjusted non-IFRS net profit is projected at USD 45.5 million to USD 51.5 million versus an adjusted net loss of USD 15.4 million previously.</p><p>The earnings inflection reflects the company's multi-pronged commercial model combining pipeline out-licensing, co-development partnerships, and AI platform services. Recent catalysts include a USD 600 million strategic collaboration with Takeda Pharmaceutical announced on July 2, and the initiation of a Phase 3 clinical trial for its lead AI-discovered drug Rentosertib on July 8.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1141701482","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141701482","pubTimestamp":1783649722,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 10, Insilico Medicine rose 5.92% in regular trading, trading at 42.4 HKD/share with turnover of HKD 282 million, extending strong momentum following its positive profit warning issued the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"走势警报|Insilico Medicine 常规交易上涨 5.92%，积极的盈利预警表明上半年扭亏为盈","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"On July 10, Insilico Medicine rose 5.92% in regular trading, trading at 42.4 HKD/share with turnover of HKD 282 million, extending strong momentum following its positive profit warning issued the previous day.On July 9, the company announced it expects first-half revenue of approximately USD 103 million to USD 107 million, representing growth of approximately 272.7% to 287.3% compared to USD 27.5 million in the same period last year. Net profit is expected at USD 33.5 million to USD 39.5 million, a significant turnaround from the net loss of USD 19.2 million recorded in the prior-year period. Adjusted non-IFRS net profit is projected at USD 45.5 million to USD 51.5 million versus an adjusted net loss of USD 15.4 million previously.The earnings inflection reflects the company's multi-pronged commercial model combining pipeline out-licensing, co-development partnerships, and AI platform services. Recent catalysts include a USD 600 million strategic collaboration with Takeda Pharmaceutical announced on July 2, and the initiation of a Phase 3 clinical trial for its lead AI-discovered drug Rentosertib on July 8.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}